News Square
Global Crypto News · Real-time Aggregation
📚 Deep Analysis
More →GRVT Burns 1.1 Million Tokens as Countdown to Grvt 2.0 Begins
<strong>[PRESS RELEASE – Singapore, Singapore, October 20th, 2026]</strong> <strong>The discretionary buyback represents close to 1% of circulating supply and precedes four planned product milestones culminating in Grvt 2.0.</strong> <a href="https://grvt.io/" rel="nofollow noopener" target="_blank">>Grvt</a>, a self-custodial trading platform built on its own zero-knowledge (ZK) chain, announced that the Foundation’s token issuer has completed its first GRVT token buyback, purchasing and burning 1.1 million GRVT tokens on the open market. The transaction permanently removed close to 1% of GRVT’s circulating supply at the time of purchase. It marks the first of five milestones ahead of the planned launch of Grvt 2.0 at the end of November 2026. <strong>A Discretionary Buyback with On-Chain Verification</strong> The Foundation’s token issuer intends to conduct further buybacks on a monthly basis. Each transaction remains entirely at the issuer’s discretion, with no predetermined purchase amount or guaranteed schedule. Buybacks are executed through an independent execution partner, with purchased tokens transferred to a designated burn address and permanently removed from circulation. The transactions can be independently verified through the <a href="https://grvt.io/exchange/buybacks" rel="nofollow noopener" target="_blank">>public buyback dashboard</a>, which records the number of tokens purchased and burned, the percentage of circulating supply represented, cumulative burns and on-chain transaction hashes. “The GRVT token is an important part of the ecosystem we are building,” said <strong>Hong, co-founder and CEO of Grvt</strong>. “We welcome the issuer’s buybacks as a demonstration of its long-term commitment to the ecosystem and community. Grvt is expanding its products and markets, and the issuer’s buybacks sit alongside that as a supportive mechanism aimed at reducing circulating token supply.” <strong>Grvt Outlines Four Product Milestones</strong> The announcement follows GRVT’s token generation event in July 2026 and precedes a series of planned launches. <strong>Grvt Earn, scheduled for the End of October,</strong> will introduce yield opportunities backed by tokenized assets, with target yields of up to 11%. Potential returns are expected to derive from underlying asset cash flows, including interest, premiums and invoice-related income. Asset-supplying partners will be announced at launch. Target yields are not guaranteed. <strong>Stable Funding Perps, scheduled for November,</strong> will introduce perpetual futures linked to commodities, stocks, foreign exchange and indices. The contracts are planned to carry zero trading fees and use once-daily funding. Grvt aims to list more than 1,000 markets by the end of December 2026. <strong>Yield as Margin, also scheduled for November,</strong> will allow eligible Grvt Earn balances to support trading positions while continuing to accrue yield, subject to applicable product terms
OpenAI Buys Orchestra Bio to Put AI Agents in Charge of Drug Development Grunt Work
OpenAI has bought Orchestra Bio, a San Francisco startup whose AI agents help drug companies keep sprawling development programs on schedule, the ChatGPT maker <a href="https://openai.com/index/openai-to-acquire-orchestra-bio/" target="_blank" rel="nofollow external noopener" class="sc-adb616fe-0 dJryYS">>announced Tuesday</a>. “Our goal is to help scientists make discoveries and manage the work needed to turn them into treatments that reach patients sooner,” OpenAI said in the announcement. Orchestra’s team and platform will be folded into <a href="https://openai.com/rosalind/" target="_blank" rel="nofollow external noopener" class="sc-adb616fe-0 dJryYS">>Rosalind</a>, OpenAI’s family of AI models and tools for biologists and chemists. The financial terms were not disclosed. Getting a new medicine from first idea to U.S. approval takes time—up to 15 years according to OpenAI. Every month shaved off that timeline is a month earlier that a new treatment can reach the people waiting for it, and a month earlier that the company can generate cash. The process is also absurdly expensive: bringing one approved drug to market can cost more than <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12668846/" target="_blank" rel="nofollow external noopener" class="sc-adb616fe-0 dJryYS">>$2.6 billion</a>, and <a href="https://arxiv.org/pdf/2106.05386" target="_blank" class="sc-adb616fe-0 dJryYS" rel="nofollow">fewer than 10%</a> of candidates that enter human testing ever make it to pharmacy shelves. Beyond the science itself, OpenAI says drug teams have to coordinate work across internal departments and outside partners, often relying on systems that don’t talk to each other. Those partners usually include contract research organizations, the outside labs hired to run studies, and contract manufacturers that produce the experimental drug. Orchestra’s AI agents—software that can watch over tasks and flag problems on its own—work out which activities and deadlines take the hit, gather the relevant information and compare ways to respond, while scientists and program leaders make the final call. Founded in the fall of 2022, Orchestra raised its <a href="https://jobs.8vc.com/companies/orchestra/jobs/28818089-senior-software-engineer" target="_blank" rel="nofollow external noopener" class="sc-adb616fe-0 dJryYS">>seed round</a> from Andreessen Horowitz, Definition Capital, Insight Partners, and 8VC, and about $20 million in total, according to <a href="https://www.caplight.com/company/orchestra-bio" target="_blank" class="sc-adb616fe-0 dJryYS" rel="nofollow">Caplight data</a>. The company should not be confused with Orchestra BioMed, an unrelated Nasdaq-listed medical device maker that trades under the ticker OBIO. In April, OpenAI launched <a href="https://decrypt.co/364783/openai-gpt-rosalind-drug-discovery-life-sciences-model" target="_blank" class="sc-adb616fe-0 dJryYS" rel="nofollow">GPT-Rosalind</a>, a model built specifically for biology and dru
Bitget launches 8 new trading instruments, including aluminum and the Hang Seng Tech Index.
Bitget has announced that its CFD product has listed eight new trading instruments, including aluminum/US dollar (xalusd), low-sulfur diesel (gasoil), Hang Seng Tech Index (hstech), and Taiwan RIC Index (twricc), covering the metals, energy, and index categories. The above metals and energy contracts support leverage of up to 20x, while the index contracts support leverage of up to 50x. In addition, these instruments will be simultaneously available under four trading modes: ecn, 0-fee, pro, and standard+, with product configurations remaining consistent across all modes.
Upbit holders airdrop launches IOST (IOST)
CoinWorld news: Upbit has announced a holder airdrop event and the listing of the IOST (IOST) token. This airdrop is the 19th periodic distribution by the IOST Foundation, with the airdrop time set for March 15, 2025, at 17:00 (UTC+8). Important notes include: the airdrop will be distributed within 24 hours after the announcement is published; the snapshot time is March 15, 2025, at 09:00:00 KST; only users who hold IOST on Upbit at the time of the snapshot are eligible to receive the airdrop; pending deposits or pending withdrawals are not counted.
Alibaba Cloud integrates its AI search business: CleverSee targets public web, industry, and enterprise internal data simultaneously.
Alibaba Cloud has merged its original iqs information query service with CleverSee, unifying and upgrading them into the CleverSee AI search service. The integration was completed on September 18, with both products now using the new brand and console, and a new version of the web search API and a web Q&A agent have been launched. CleverSee primarily targets enterprises and AI agents, integrating retrieval capabilities across the public internet, industry-specific professional data, and enterprises' internal materials. The service is divided into three major sections by information source: web search and Q&A, vertical-domain search and Q&A, and enterprise search and Q&A. In terms of pricing, CleverSee's domestic web search fast version costs 8 yuan per thousand calls, the smart version costs 18 yuan, and the web Q&A agent lite version costs 18 yuan per thousand calls.
The SOL contract's active buy volume share over the past 4 hours is 47.4%.
CoinWorld data: Over the most recent 4 complete hours, the taker buy share of SOLUSDT perpetual contract trades was 47.4%, while the taker sell share was 52.6%, with taker selling dominating. Compared with the same-methodology snapshot 24 hours earlier, it fell by 4.7594 percentage points; compared with the same-methodology snapshot 7 days earlier, it fell by 3.9738 percentage points.
blockchain.com and Binance US seek to launch prediction markets in the United States
Crypto exchanges such as blockchain.com and Binance US are seeking to launch prediction markets in the United States in search of new revenue streams, according to the Financial Times.
Bank of Japan Deputy Governor Ryozo Himino: Recently made seven consecutive remarks.
According to CoinWorld news, Bank of Japan Deputy Governor Ryozo Himino has recently made the following remarks in succession: First, strong demand for artificial intelligence is driving growth in capital expenditure and exports. Second, the underlying inflation rate is now quite close to the Bank of Japan's 2% target. Third, underlying inflation is expected to approach a level consistent with the Bank of Japan's target. Fourth, medium- to long-term inflation expectations continue to rise, and financial conditions remain accommodative. Fifth, real interest rates remain low, and bank lending is growing rapidly. Sixth, delaying policy adjustments could pose inflation risks and harm the economy. Seventh, upside risks to prices are high.
Cointelegraph: Multiple crypto exchanges accelerate the launch of prediction markets to counter the token decline.
According to Cointelegraph, as token prices continue to decline, several cryptocurrency exchanges, including Blockchain.com and Binance US, are accelerating the launch of prediction markets in search of new revenue streams.
The active buy volume share of ETH contracts over the past 4 hours is 50.34%.
CoinWorld data: Over the most recent 4 complete hours, the taker buy volume share of the ETHUSDT perpetual contract was 50.34%, while the taker sell share was 49.66%, with taker buying prevailing. Compared with the same-methodology snapshot 24 hours earlier, it rose by 2.2218 percentage points; compared with the same-methodology snapshot 7 days earlier, it fell by 1.4622 percentage points.